The role of N-cadherin, MCAM and β3 integrin in melanoma progression, proliferation, migration and invasion

Cancer Biology and Therapy

Volumn 5, Issue 10, 2006, Pages 1375-1382

  Watson Hurst, Kelly ^a   Becker, Dorothea ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion molecules; Functional analysis; Melanoma

Indexed keywords

BETA3 INTEGRIN; CELL ADHESION MOLECULE; GLYCOPROTEIN MCAM; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE MICROARRAY; TUMOR GROWTH;

EID: 33751088793     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.10.3241     Document Type: Article

References (21)

1. Holzmann B, Brocker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmuller G, Johnson JP. Tumor progression in human malignant melanoma: Five stages defined by their antigenic phenotypes. Int J Cancer 1987; 39:466-71.
2. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: Association of the beta3 subunit with tumor progression. Cancer Res 1990; 50:6757-64.
3. Hsu MY, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Invest Dermatol 1996; 1:188-94.
4. Cavallaro U. N-cadherin as an invasion promoter: A novel target for antitumor therapy? Curr Opin Investig Drugs 2004; 5:1274-8.
5. Hsu MY, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, Herlyn M. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and downregulates expression of invasion-related adhesion receptors. Am J Pathol 2000; 156:1515-25.
6. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001; 61:3819-25.
7. Lehmann JM, Holzmann B, Breitbart EW, Schiegelow P, Riethmuller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 1987; 47:841-5.
8. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 1994; 54:2514-20.
9. Wang Y, Rao U, Mascari R, Richards TJ, Panson AJ, Edington HD, Shipe-Spotloe JM, Donnelly SS, Kirkwood JM, Becker D. Molecular analysis of melanoma precursor lesions. Cell Growth Differ 1996; 7:1733-40.
10. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997; 57:2295-303.
11. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 2001; 20:4676-84.
12. Voura EB, Ramjeesingh RA, Montgomery AMP, Siu CH. Involvement of integrin alphavbeta3 and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell 2001; 12:2699-710.
13. Hsu MY, Shih DT, Meier F, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998; 153:1435-42.
14. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. The EMBO Journal 1989; 8:3685-91.
15. Smith A, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 2005; 4:1018-29.
16. Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000; 14:704-18.
17. Hildebrandt T, van Dijk MC, van Muijen GN, Weidle UH. Loss of heterozygosity of gene THW is frequently found in melanoma metastases. Anticancer Research 2001; 21:1071-80.
18. Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 2003; 22:6891-9.
19. Zheng DQ, Woodard AS, Tallini G, Languino LR. Substrate specificity of αvβ3 integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 2000; 275:24565-74.
20. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3:887-93.
21. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R. A Phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monocloncal antibody directed against the human alpha v beta 3 (avb3) integrin, +/- dacarbazine (DTIC) in patients with metastatic melanoma (MM). ASCO Annual Meeting 2005.